Most Undervalued Stocks Based on Predictive Analytics : Returns up to 62.19% in 1 Month
Recommended Positions: Short
Forecast Length: 1 Month (09/30/2018 - 10/30/2018)
I Know First Average: 24.63%
“With the preliminary data from IMerge presented at ASH, we now have clinical data in three blood cancers, ET, MF and MDS, where imetelstat exhibits potential disease modifying activity by inhibiting the progenitor cells of the malignant clones that drive the underlying diseases”
– said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer.
(Image Source: www.troutaccess.com)
Geron Corporation (NASDAQ: GERN) operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the
Disclaimer:
I Know First-Daily Market Forecast, does not provide personal investment or financial advice to individuals, or act as personal financial, legal, or institutional investment advisors, or individually advocate the purchase or sale of any security or investment or the use of any particular financial strategy. All investing, stock forecasts and investment strategies include the risk of loss for some or even all of your capital. Before pursuing any financial strategies discussed on this website, you should always consult with a licensed financial advisor.